(74 days)
No
The description focuses on the mechanical properties, materials, and surgical placement of a physical implant, with no mention of software, algorithms, or data processing that would indicate AI/ML.
Yes.
The device is intended to treat osteoarthritis by reducing pain and improving knee alignment and joint function, which are therapeutic effects.
No
The device is an implantable medical device designed to treat osteoarthritis in the knee by replacing lost cartilage and improving alignment. It is not used to diagnose a medical condition.
No
The device description clearly states it is a physical implant made of Cobalt-Chrome-Molybdenum Alloy, intended for surgical placement in the knee. It also mentions surgical instruments. This is a hardware medical device, not software-only.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Description: The OrthoGlide Lateral Knee Implant is a physical implant placed inside the body during surgery. It is a prosthetic device designed to replace damaged cartilage and improve knee function.
- Intended Use: The intended use is for the treatment of osteoarthritis in the knee by providing an articulating surface and improving alignment. This is a therapeutic intervention, not a diagnostic test performed on a specimen.
The provided text clearly describes a surgically implanted medical device, not a device used for testing biological samples outside the body.
N/A
Intended Use / Indications for Use
The OrthoGlide Lateral Knee Implant is intended for use in the osteoarthritic knee, where substantial amounts of cartilage have been lost as a result of the disease. The device is indicated for uncemented use in the treatment of moderate degeneration of the lateral compartment of the knee (grade II-IV chondromalacia) with no more than minimal degeneration (grade I-II chondromalacia, no loss of joint space) in the medial and patellofemoral compartments in patients with osteoarthritis.
Product codes
HSH
Device Description
The OrthoGlide Lateral Knee Implant is placed in the lateral compartment of the knee between the tibial plateau and femoral condyle by means of minimally invasive surgery. The instruments are intended to aid in the surgical preparation of the implant site and implant placement. The OrthoGlide is made of a Cobalt-Chrome-Molybdenum Alloy. Device geometry and ligament tension combine to keep the implant in place. The implant covers the lateral tibial plateau. The device is designed to improve the alignment of the knee, returning the joint to a less valgus position. Realignment of the knee distributes the weight-bearing forces across the joint and helps restore the normal relationships of the articular surfaces and the surrounding capsular, ligamentous and muscular structures.
The device is designed to help relieve pain by providing an articulating surface with a low coefficient of friction and high durability. Device geometry improves knee alignment and joint spacing. The device surface is smooth and when wet, is intended to mimic the lubricious surface previously provided by the articular cartilage.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
lateral compartment of the knee, tibial plateau, femoral condyle, medial and patellofemoral compartments
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The OrthoGlide Implant has been developed, verified and validated in compliance with a comprehensive design process. The corresponding Bench Testing has been accomplished according to a Master Test Plan for the device. The test plan shows the required test, the source of the requirement, the protocol and the report. If the method is from a standard, the voluntary standard is referenced. The bench testing has demonstrated the physical attributes and durability of the OrthoGlide by tensile elongation, load deflection, cyclic fatigue resistance, material consistency and stability and processing control.
Cadaver testing has verified the surgical technique and instruments. Cadaver evaluations have also verified the desired physiological effects of stability and range of motion preservation.
The OrthoGlide also demonstrated that it meets internationally recognized standards for biocompatibility (ISO 10993), sterility (EN550), and conformance to material specifications. Clinical testing was not used to determine substantial equivalence.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3590 Knee joint tibial (hemi-knee) metallic resurfacing uncemented prosthesis.
(a)
Identification. A knee joint tibial (hemi-knee) metallic resurfacing uncemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits minimally (less than normal anatomic constraints) translation in one or more planes. It has no linkage across-the-joint. This prosthesis is made of alloys, such as cobalt-chromium-molybdenum, and is intended to resurface one tibial condyle. The generic type of device is limited to those prostheses intended for use without bone cement (§ 888.3027).(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo for Advanced Bio-Surfaces, Inc. The logo consists of the letters "ABS" in a bold, sans-serif font, with the words "ADVANCED BIO-SURFACES, INC." printed below. To the right of the letters is a graphic of three horizontal lines, with the top and bottom lines being curved and the middle line being straight. The letters and text are black, and the background is white.
Ko73233 (pg 1/3)
510(k) Summary
Advanced Bio-Surfaces, Inc.
OrthoGlide® Lateral Knee Implant
JAN 28 2005
510(k) Notification
MANUFACTURER INFORMATION
-
Advanced Bio-Surfaces, Inc. Name & Address: 5909 Baker Road, Suite 550 Minnetonka, MN 55345 USA
Summary Prepared: November 12, 2007 -
Contact: Albert Schafer Manager, Q.A. / Regulatory Affairs 952-912-5400 phone 952-912-5410 fax
DEVICE INFORMATION
Trade Name: OrthoGlide® Lateral Knee Implant
Classification Name: 21CFR 888.3590 - Knee joint tibial (hemi-knee) metallic resurfacing uncemented prosthesis · ·· ·- ·- ··· ·············· ·· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Product Code: HSH
. . . .-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Common / Usual Name: Hemi- knee prosthesis
Substantial equivalence: The ABS OrthoGlide Lateral Knee Implant is substantially
equivalent to FDA approved predicate devices with regard to indications for use,
materials, technological characteristics and surgical techniques. These predicate devices
Sulzer Orthopedics, Inc. Unicondylar Interpositional Spacer (K003269) are:
ITI, Knee Interpositional Mini-Repair system (KIMRS) (K033242)
Advanced Bio Surfaces, Inc. OrthoGlide Lateral 510(k) Premarket Notification
Confidential Section 5 Page 1 of 3
1
ABS OrthoGlide® Medial Knee Implant (K053094)
Device Description: The OrthoGlide Lateral Knee Implant is placed in the lateral compartment of the knee between the tibial plateau and femoral condyle by means of minimally invasive surgery. The instruments are intended to aid in the surgical preparation of the implant site and implant placement. The OrthoGlide is made of a Cobalt-Chrome-Molybdenum Alloy. Device geometry and ligament tension combine to keep the implant in place. The implant covers the lateral tibial plateau. The device is designed to improve the alignment of the knee, returning the joint to a less valgus position. Realignment of the knee distributes the weight-bearing forces across the joint and helps restore the normal relationships of the articular surfaces and the surrounding capsular, ligamentous and muscular structures.
The device is designed to help relieve pain by providing an articulating surface with a low coefficient of friction and high durability. Device geometry improves knee alignment and joint spacing. The device surface is smooth and when wet, is intended to mimic the lubricious surface previously provided by the articular cartilage.
- The OrthoGlide Lateral Knee Implant is intended for use in the Intended Use: osteoarthritic knee, where a substantial amount of cartilage has been lost as a result of the disease. The device is indicated for uncemented use in the treatment of moderate degeneration of the Lateral compartment of the knee (grade II-IV chondromalacia) with no more than minimal degeneration (grade I-II chondromalacia, no loss of joint space) in the medial and patellofemoral compartments in patients with osteoarthritis.
2
Substantial Equivalence: The ABS OrthoGlide Lateral Knee Implant is substantially equivalent to FDA approved predicate devices with regard to indications for use, materials, technological characteristics and surgical techniques. OrthoGlide offers no additional risks to the patient and the materials and manufacturing methods add no new or additional safety concerns. The OrthoGlide as well as the predicates are submitted without clinical information. The substantially equivalent predicate devices are:
Sulzer Orthopedics, Inc. Unicondylar Interpositional Spacer (K003269)
ITI, Knee Interpositional Mini-Repair system (KIMRS) (K033242)
ABS OrthoGlide Medial Knee Implant (K053094)
Testing: The OrthoGlide Implant has been developed, verified and validated in compliance with a comprehensive design process. The corresponding Bench Testing has been accomplished according to a Master Test Plan for the device. The test plan shows the required test, the source of the requirement, the protocol and the report. If the method is from a standard, the voluntary standard is referenced. The bench testing has demonstrated the physical attributes and durability of the OrthoGlide by tensile elongation, load deflection, cyclic fatigue resistance, material consistency and stability and processing control.
Cadaver testing has verified the surgical technique and instruments. Cadaver evaluations have also verified the desired physiological effects of stability and range of motion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . preservation. .. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The OrthoGlide also demonstrated that it meets internationally recognized standards for biocompatibility (ISO 10993), sterility (EN550), and conformance to material specifications. Clinical testing was not used to determine substantial equivalence.
Summary: Based on the evidence of substantial equivalence the OrthoGlide is considered to be safe and effective and will perform as well or better than the referenced predicate devices.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird in flight, with three curved lines representing the wings and body. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the bird symbol.
Public Health Service
JAN 28 2008
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Advanced Bio-Surfaces, Inc. % Mr. Albert Schafer Manager, Q.A./Regulatory Affairs 5909 Baker Road, Suite 550 Minnetonka, MN 55345
Re: K073233 Trade/Device Name: OrthoGlide® Lateral Knee Implant Regulation Number: 21 CFR 888.3590 Regulation Name: Knee joint tibial (hemi-knee) metallic resurfacing uncemented prothesis Regulatory Class: II Product Code: HSH Dated: December 30, 2007 Received: January 29, 2008
Dear Mr. Schafer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 - Mr. Albert Schafer
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance. please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html
Sincerely yours,
Mark M. Mulheran
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Eyaluation Center for Devices and Radiological Health
Enclosure
5
K0732333 (pg 1/ 门
Indications for Use
510(k) Number (if known):
Device Name: OrthoGlide® Lateral Knee Implant
Indications for Use:
The OrthoGlide Lateral Knee Implant is intended for use in the osteoarthritic knee, where substantial amounts of cartilage have been lost as a result of the disease. The device is indicated for uncemented use in the treatment of moderate degeneration of the lateral compartment of the knee (grade II-IV chondromalacia) with no more than minimal degeneration (grade I-II chondromalacia, no loss of joint space) in the medial and patellofemoral compartments in patients with osteoarthritis.
Prescription Use _ Yes (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use No (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Posted November 13, 2003)
Mark N. MilkenPage1 of1
Division Sign-Off Division of General, Restorative, and Neurological Devices
510(k) Number K073233